Pfizer data has positive read-through for uniQure, says H.C. Wainwright

After Pfizer (PFE) announced top-line data from the Phase 3 BENEGENE-2 trial of gene therapy fidanacogene elaparvovec for the treatment of adult males with moderately severe to severe hemophilia B, H.C. Wainwright analyst Patrick Trucchio said the data demonstrate comparable ABR reduction, lower FIX activity, and "a more complicated safety profile" when compared to uniQure’s (QURE) Hemgenix, which was approved by the FDA in November. The analyst, who believes the BENEGENE-2 data confirm his thesis that Hemgenix "should become the leading HB gene therapy on the market," reiterates a Buy rating and $90 price target on uniQure shares.